Pharma Results. Natural Delivery. · Exclusively Distributed by ORYGN*
Peer-reviewed clinical research, independent trials, and global recognition — every product backed by uncompromising evidence.
Peer-Reviewed Research
Over $50 million invested and more than a decade of independent research. A curated index of peer-reviewed studies and clinical trials supporting the core bioactives in every ORYGN product.
In The Press
Real coverage from trade press, financial media, and industry publications — tracking the science, the deals, and the momentum behind ProGo® and Fission Holdings.
HBC entered into an Exclusive License and Supply Agreement granting Fission Holdings worldwide rights to market and sell ProGo® in the affiliate, network marketing, and MLM channel. Fission shall purchase a minimum of $3M of ProGo® by January 31, 2027, with an annualised projection of over $5M.
Regulatory Recognition
ProGo® has earned the highest levels of regulatory recognition available in North America — an NDI designation from the FDA, thirteen FDA Structure/Function Claims, and four Qualified Health Claims from Health Canada. These are not marketing statements. They are government-recognized, science-backed, and legally defensible.
ProGo® has received FDA New Dietary Ingredient (NDI) status — the highest safety rating available in the US market. NDI classification confirms ProGo® is both safe for human consumption and legally marketable as a dietary supplement ingredient in the United States.
View FDA AnnouncementProGo® raw material has been granted approval by the Non-GMO Project — enabling co-branding on premium consumer product packaging and unlocking distribution through organic and natural retail channels including Nestlé-owned Garden of Life.
Health Canada's Qualified Health Claims (QHCs) are internationally recognized by most Asian countries and have been passported for use in those markets — enabling ORYGN to leverage regulatory credibility across Japan, South Korea, China, and the broader Asia-Pacific region.
United States Food & Drug Administration
The FDA did not oppose any of HBC's claim notices within the statutory review period — confirming ProGo® is legally permitted to carry the following claims on US-market labels and marketing materials.
Health Canada · Qualified Health Claims
Following an extensive scientific assessment by Canadian health authorities, ProGo® became the first and only non-iron product in Canada to receive regulatory approval for iron health claims — confirming its effect in the treatment of iron deficiency anemia. These claims are also internationally recognized across most Asian countries.
These claims apply specifically to ProGo® bioactive peptides as manufactured and supplied by Hofseth BioCare ASA. Structure/Function Claims are compliant with 21 CFR 101.93. Health Canada Qualified Health Claims are regulated under the Natural Health Products Regulations. All claims are the regulatory property of HBC and are licensed for use by Fission Holdings LLC and ORYGN within the permitted distribution channel.
Global Footprint
Over $50M invested. A decade of peer-reviewed studies. Distribution across 80+ countries on every continent.
Partnerships & Endorsements
ORYGN licenses ProGo® under Fission Holdings, LLC, which holds the worldwide exclusive rights to import, market, distribute, and sell ProGo® within the Affiliate, Network Marketing, and MLM channel — working alongside the world's leading research institutions, clinical partners, and distribution organisations.
ORYGN has licensed ProGo® distribution from Fission Holdings LLC, which holds the worldwide exclusive rights to import, market, distribute, and sell HBC's ProGo® ingredient within the Affiliate, Network Marketing, and Multi-Level Marketing (MLM) channel — the only company in the world authorized to do so. This exclusivity is secured by multi-million dollar purchase guarantees, confirmed by Hofseth BioCare ASA's official Oslo Børs stock exchange announcement on May 22, 2026.
View Official HBC Announcement